Endonovo Therapeutics is a clinical-stage bioelectronic medicine company that develops noninvasive, electroceutical therapies designed to address inflammation, pain management, wound healing and tissue regeneration. Headquartered in San Diego, California, the company applies its proprietary capacitive-resistive electric transfer (CRET) technology to deliver low-intensity, alternating radiofrequency currents through wearable devices. Endonovo’s platform is intended to activate endogenous repair mechanisms, promote cellular recovery and enhance patient outcomes across a variety of therapeutic applications.
Founded in 2010 under its original name, Endonovo transitioned from a broader oncology research focus into the emerging field of bioelectronic medicine in 2021. Since that strategic pivot, the company has advanced multiple product candidates through preclinical and early clinical studies, including pilot trials in South America and the United States. These trials explore indications such as chronic musculoskeletal pain, diabetic foot ulcers, postoperative recovery and sports-related injuries. Endonovo collaborates with academic institutions and clinical partners to validate its therapies and refine treatment protocols for commercial deployment.
Endonovo serves markets across North and South America through direct sales channels and distribution agreements. Its devices are designed for ease of use in hospital, clinic and home-care settings, enabling practitioners to integrate bioelectronic treatments into existing care pathways. The company’s leadership team combines expertise in biomedical engineering, regenerative medicine and medical device commercialization, bolstered by a board of directors with backgrounds in life-science innovation and health-care operations. Looking ahead, Endonovo aims to expand its product portfolio and regulatory clearances to address a broader range of inflammatory and degenerative conditions worldwide.
AI Generated. May Contain Errors.
